Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study
Published March 2026
Steiner SJ, Adler J, Saeed SA, Strauss RS, Howe KM, Sheahan A, Zhang R, Keihn KR, Harrow K, Olano KK, Evans DA, Lo KH, Zhang N, Kim L, Colletti RB, Volger S, ImproveCareNow Learning Health Network. Effectiveness and safety of ustekinumab in pediatric Crohn's disease: results of the REALITI study. J Pediatr Gastroenterol Nutr. 2026;1-9. doi:10.1002/jpn3.70372
Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real-world clinical settings for children with CD
Read more from the News announcement of this study
The Development and Co-Production of a Caregiver Coping Resource for Pediatric Inflammatory Bowel Disease and Autoimmune Liver Disease
Published February 2026
Caregivers of children with chronic conditions have mental health needs, with no known resources for caregiver coping in pediatric Inflammatory Bowel Disease (IBD) and autoimmune liver disease (AILD), which can be co-morbid. Quality improvement (QI) has previously co-produced resources within Learning Health Networks (LHNs). This QI work sought to co-produce a caregiver coping resource for caregivers of children with IBD and/or AILD.
Read more about the Caregiver Coping Resource on LOOP
Risk factors at diagnosis for progression to severe colitis and colectomy in children and young adult patients with mild-moderate disease
Published February 2026
, , , , . Risk factors at diagnosis for progression to severe colitis and colectomy in children and young adult patients with mild-moderate disease. J Pediatr Gastroenterol Nutr. 2026; 1-8. doi:10.1002/jpn3.70382
Pediatric ulcerative colitis (UC) has a more severe and unpredictable course than adult-onset disease. This study aimed to identify baseline and time-varying risk factors for the development of severe disease or colectomy among children and young adults with mild to moderate UC.
The improvecarenow registry: Prediction of 2-year nonremission in pediatric ulcerative colitis
Published February 2026
, , , et al. The improvecarenow registry: Prediction of 2-year nonremission in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2026; 1-10. doi:10.1002/jpn3.70370
Identifying predictors of unfavorable disease course in pediatric ulcerative colitis (UC) will impact therapeutic strategy. We aimed to define predictors of nonremission 2 years after diagnosis in pediatric patients with UC.
Poster presented at Digestive Disease Week 2025
Development and testing of a pediatric inflammatory bowel disease medical transfer summary
Published February 2026
, , , . Development and testing of a pediatric inflammatory bowel disease medical transfer summary. J Pediatr Gastroenterol Nutr. 2026. doi:10.1002/jpn3.70349
We describe the multidisciplinary development and testing of a standardized pediatric IBD medical transfer summary template (PIBD-MTS) as a tool to improve the handoff of patient care.
Symptom cluster profiles in adolescents with inflammatory bowel disease: Cross-sectional study using ImproveCareNow data
Malloy C, Kroenke K, Monahan PO, Rawl SM, Steiner SJ, Miller WRT; ImproveCareNow Pediatric IBD Learning Health System. Symptom cluster profiles in adolescents with inflammatory bowel disease: Cross-sectional study using ImproveCareNow data. J Pediatr Gastroenterol Nutr. 2026 Jan 29. doi: 10.1002/jpn3.70365. Epub ahead of print. PMID: 41609007.
Published January 2026
Sleep disturbance, pain, anxiety, depression, and fatigue are prevalent in adolescents and young adults with inflammatory bowel disease (IBD). These symptoms often present in co-occurring sets, known as symptom clusters. We aimed to identify distinct symptom clusters and factors associated with symptom profiles in adolescents with IBD.
Poster presented at Digestive Disease Week 2025.